Results 61 to 70 of about 1,247,684 (370)

Clinical commissioning of an adaptive radiotherapy platform: Results and recommendations

Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Online adaptive radiotherapy platforms present a unique challenge for commissioning as guidance is lacking and specialized adaptive equipment, such as deformable phantoms, are rare. We designed a novel adaptive commissioning process consisting of end‐to‐end tests using standard clinical resources.
Kelly Kisling, Timothy D. Keiper, Daniela Branco, Grace Gwe‐Ya Kim, Kevin L Moore, Xenia Ray   +5 more
wiley   +1 more source

The impact of pre‐biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review

BJUI Compass
Objective This work aims to examine the latest evidence on the impact of pre‐biopsy MRI, in addition to prostate‐specific antigen (PSA) testing, on health outcomes and quality of life.
Abel Tesfai, Natalia Norori, Thomas A. Harding, Yui Hang Wong, Matthew David Hobbs   +4 more
doaj   +1 more source

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Treatment planning with a 2.5 MV photon beam for radiation therapy

Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Purpose The shallow depth of maximum dose and higher dose fall‐off gradient of a 2.5 MV beam along the central axis that is available for imaging on linear accelerators is investigated for treatment of shallow tumors and sparing the organs at risk (OARs) beyond it.
Navid Khaledi, Chris Hayes, Louise Belshaw, Mark Grattan, Rao Khan, James L. Gräfe   +5 more
wiley   +1 more source

Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review

BJUI Compass
Objective To analyse the latest evidence on the relative harms and benefits of screening and diagnostic pathways with close examination of (i) men aged 50 years or older, (ii) men whose ethnicity places them at higher risk and (iii) men with a family ...
Abel Tesfai, Natalia Norori, Thomas A. Harding, Yui Hang Wong, Matthew David Hobbs   +4 more
doaj   +1 more source

Conducting Clinical Research in Low Research Resource Countries: Lessons Learned From the International Registry of Men With Advanced Prostate Cancer Study in Nigeria

JCO Global Oncology
PURPOSEThere is limited cancer clinical research in sub-Saharan African countries despite the significant burden of cancers. The primary objective of this strengths, weaknesses, opportunities, and threats (SWOT) analysis was to understand and document ...
Opeyemi Bolajoko, Parisa Fathi, Dottington Fulwood, Oluwaseyi Toye, Ademola Popoola, Hassan Dogo, Haruna Nggada, Chidiebere Ogo, Omolara Fatiregun, Mohammed Faruk, Lateef Abiodun, Anthonia Sowunmi, Catherine A. Oladoyinbo, Folakemi Odedina   +13 more
doaj   +1 more source

Prospective identification of tumorigenic prostate cancer stem cells.

Cancer Research, 2005
Existing therapies for prostate cancer eradicates the bulk of cells within a tumor. However, most patients go on to develop androgen-independent disease that remains incurable by current treatment strategies.
A. Collins, P. Berry, Catherine Hyde, M. Stower, N. Maitland   +4 more
semanticscholar   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Validation of pencil beam scanning proton therapy with multi‐leaf collimator calculated by a commercial Monte Carlo dose engine

Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract This study aimed to evaluate the clinical beam commissioning results and lateral penumbra characteristics of our new pencil beam scanning (PBS) proton therapy using a multi‐leaf collimator (MLC) calculated by use of a commercial Monte Carlo dose engine.
Yuki Tominaga, Yusuke Sakurai, Junya Miyata, Shuichi Harada, Takashi Akagi, Masataka Oita   +5 more
wiley   +1 more source

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

New England Journal of Medicine, 2016
BACKGROUND Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected ...
C. Pritchard, J. Mateo, M. Walsh, N. Sarkar, W. Abida, H. Beltran, A. Garofalo, R. Gulati, S. Carreira, R. Eeles, O. Elemento, M. Rubin, Daniel H. Robinson, R. Lonigro, M. Hussain, A. Chinnaiyan, A. Chinnaiyan, J. Vinson, J. Filipenko, L. Garraway, M. Taplin, S. AlDubayan, G. Han, Mallory Beightol, C. Morrissey, Belinda Nghiem, Heather H. Cheng, B. Montgomery, T. Walsh, S. Casadei, S. Casadei, M. Berger, Liying Zhang, A. Zehir, J. Vijai, H. Scher, C. Sawyers, N. Schultz, P. Kantoff, D. Solit, M. Robson, E. Allen, K. Offit, J. Bono, Peter S. Nelson, P. Nelson   +45 more
semanticscholar   +1 more source